Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gains from Sales and Divestitures: 2014-2016

Historic Gains from Sales and Divestitures for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Dec 2016 value amounting to $52,668.

  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures fell 88.53% to $52,668 in Q4 2016 from the same period last year, while for Dec 2016 it was $52,668, marking a year-over-year decrease of 88.53%. This contributed to the annual value of $52,668 for FY2016, which is 88.53% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Gains from Sales and Divestitures stood at $52,668 for FY2016, which was down 88.53% from $459,208 recorded in FY2015.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures peaked at $459,208 during FY2015, and registered a low of $52,668 during FY2016.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures had a median value of $284,893 in 2014 and averaged $265,590.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures soared by 61.19% in 2015 and then plummeted by 88.53% in 2016.
  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures (Yearly) stood at $284,893 in 2014, then skyrocketed by 61.19% to $459,208 in 2015, then slumped by 88.53% to $52,668 in 2016.